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Background: Aromatase inhibitors (AIs) have not been used consistently as part of the management of hormone
receptor positive uterine leiomyosarcomas (ULMS). As a result, the published data regarding the efficacy of AIs in
this subtype of ULMS are sparse.
Methods: We performed a retrospective electronic medical record review of patients with ULMS treated with an AI,
in the 1st or the 2nd line setting, at the Sarcoma Unit of the Royal Marsden Hospital between 2001 and 2012. We
assessed progression-free survival (PFS), objective response and toxicities and explored the correlation of the intensity
of the hormone receptor status, as well as of the grade with PFS.
Results: Sixteen patients with measurable advanced ULMS were treated with an AI in our unit. All of them were
oestrogen receptor (ER) and progesterone receptor (PgR) positive. Letrozole was used in all patients as 1st line
endocrine therapy, while exemestane was mainly prescribed as 2nd line (83%). Median PFS in 1st line was
14 months (95% CI: 0 – 30 months), and prolonged PFS was more likely to be observed in patients with low grade
compared to high grade ULMS (20 months vs. 11 months), and in moderately/strongly ER positive compared to
weakly ER positive ULMS (20 months vs. 12 months). Best response was partial response (PR) in 2/16 patients
(12.5%) and clinical benefit (CB), defined as complete response (CR) + PR + stable disease ≥6 months, was
observed in 10/16 patients (CB rate (CBR) 62.5%). Median duration of 2nd line was 3 months and median PFS was
not reached. The 1-year progression-free rate for the 2nd line AI was 80%. Best response was PR in one patient
and CBR was 50%. AIs were well tolerated in both lines of treatment.
Conclusions: In this population of patients with hormone positive ULMS, AIs achieved a significant CBR (62.5%) in
1st line, which was retained in 2nd line (CBR: 50%). The relatively prolonged median PFS (14 months), along with
the favourable toxicity profile could place AIs among the first choices of systemic treatment in hormone positive
ULMS, preferably in strongly positive (>90%), and/ or low grade and low volume disease.
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Uterine leiomyosarcomas (ULMS) account for 1–2% of
all uterine malignancies [1]. They exhibit an aggressive
natural history, with recurrence rates of 50-70% and an
overall 5-year survival of less than 50% in early stages
and less than 15% in advanced stages [2]. The mainstay
of treatment of localized ULMS comprises total abdominal
hysterectomy (TAH), bilateral salpingo-oophorectomy
(BSO) and excision of all resectable tumours [2]. In the
absence of established adjuvant treatment, depending* Correspondence: eirini.thanopoulou@nhs.net
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article, unless otherwise stated.on the histopathological report (i.e. surgical margins,
size, grade etc.) adjuvant chemotherapy, radiotherapy or
combined treatment are sometimes offered [3-5]. For
women with advanced, unresectable ULMS, chemother-
apy is given with palliative intent; however, the median
duration of response is limited to 6–8 months [6-8].
Therapeutic options are limited for patients who pro-
gress following standard chemotherapeutic regimens,
although recently the multitargeted tyrosine kinase
inhibitor pazopanib has been approved for this indica-
tion [9]. Thus, there is an urgent need to identify new
active treatments.entral Ltd. This is an Open Access article distributed under the terms of the
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oestrogen receptor (ER) and progesterone receptor
(PgR) expression [1]. In ULMS, ER has been reported to
be positive in 25–60% of cases and PgR in 35–60%
respectively [10-13]. Aromatase inhibitors (AIs) have
been introduced in the treatment of ULMS [1]. The
main mechanism of action is inhibition of aromatase
activity in peripheral adipose tissue, resulting in pro-
found reduction in circulating oestrogen levels [1]. AIs
may also inhibit directly the aromatase activity in
tumour tissue [12].
Few data are available about hormone-positive ULMS;
mainly with case reports [14], small retrospective studies
[15,16] and recently one prospective single-arm phase II
clinical trial [17]. According to this trial (27 patients),
letrozole met the protocol definition of active agent in
metastatic ULMS that was ER and/or PgR positive [17].
The benefit, in terms of prolongation of PFS, was
significant in patients with strongly (>90%) ER and PR
tumours [17]. This observation, in line with previous
retrospective studies [16], suggested that oestrogen
manipulation possibly has an active role in disease
control of this subtype of ULMS [17].
AIs have a favourable toxicity profile with the majority
of side effects being mild and attributed to the oestrogen
deprivation they induce [1,16,17]. They are administered
at the same dosages as in breast cancer treatment [1].
With this in mind, we sought to record our single insti-
tution’s experience in treating ULMS patients with AIs.
Methods
We performed a retrospective study of patients with
ULMS treated with an AI at the Sarcoma Unit of the
Royal Marsden Hospital (RMH) from January 2001 to
July 2012. Patients were identified using the prospective
Sarcoma Unit database and confirmed by pharmacy
records. Patients were excluded if they had received an
AI as treatment for breast cancer or received concomi-
tant chemotherapy. Patients’ electronic medical records
were reviewed for age at diagnosis, stage, sites of
metastases, volume of metastatic disease, tumour grade,
hormone receptor status (ER and PgR), performance
status, prior treatments, type and dose of AI used and
toxicities. In addition, we recorded the presence or ab-
sence of co-morbidities.
All patients had surgical biopsies reviewed by the
RMH Department of Pathology (two dedicated soft
tissue pathologists), which confirmed the diagnosis of
ULMS and tumour grade. Currently, there is no formally
validated grading system for ULMS. In the absence of
one, the French Federation of Cancer Centers Sarcoma
Group (FNCLCC) system has been used in RMH, as for
other sarcomas [18]. In some centres, the Bell criteria
for uterine smooth muscle tumours (or Stanford USMTcriteria) are used [16,19]. When these criteria are strictly
applied, ULMS are defined as intrinsically high grade,
although low grade ULMS may still exist [20].
Immunohistochemistry for ER and PgR was performed
on formalin fixed, paraffin embedded, representative,
whole sections of tumour. Deparaffinized tumour sec-
tions were stained for ER and PgR (both supplied pre-
diluted from Ventana Systems UK Ltd, Salisbury, UK)
using heat-induced epitope retrieval. Appropriate posi-
tive and negative controls were used throughout. ER
and PgR status was determined semi-quantitatively
and assigned as ‘weak’, ‘moderate’ or ‘strong’ in tumour
nuclei.
The primary end-point of the study was PFS for the
patients with advanced disease, and disease-free survival
(DFS) for the adjuvant patients, defined in both cases as
time from the start of AI treatment until disease pro-
gression or death from any cause, with censoring of
patients who were lost or had reached neither endpoint
at date of last follow-up. The Kaplan–Meier method was
used to estimate PFS. Objective response rate (ORR), i.e.
the rate of CR and PR, and clinical benefit rate (CBR),
i.e. the rate of CR, PR, and SD for at least 6 months
were evaluated by Response Evaluation Criteria in Solid
Tumours (revised RECIST guideline, version 1.1) criteria
[21]. The tumour assessments were performed with
computerised tomography (CT) every 2 months for the
first 12 months and then every 3 months thereafter.
We explored the correlation of ER/PgR status and
tumour grade with objective response and PFS. Toxicity
was graded using the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events (CTCAE)
version 4.02.
The study was approved by the Committee for Clinical
Research of RMH.
Results
Patient and tumour characteristics
We identified 29 patients with ULMS treated with an AI
from January 2001 to July 2012. We excluded 8 cases
that were treated in another institution and 5 patients
that did not have evidence of measurable disease at the
time of AI initiation. The demographics and tumour
characteristics of the remaining 16 patients with ad-
vanced measurable disease are listed in Table 1 and their
tumour characteristics are listed in Table 2. The median
age at time of AI initiation as 1st line hormonal treat-
ment was 55 years (range 39–72). Fourteen patients
(87.5%) were postmenopausal at the time of treatment.
Tumours were classified according to FNCLCC
criteria, as low-grade ULMS in 7 patients (44%), inter-
mediate grade in 3 (19%) patients and high-grade
ULMS in 6 patients (44%). We also classified our
patients according to Stanford USMT criteria; 8 patients
Table 1 Patient characteristics in the 1st line endocrine
setting (n = 16)
Variable n (%), median (range)
Median age at AI initiation 55 years (39–72)
Performance status
0 4 (25%)
1 10 (62.5%)
2 1 (6.25%)
3 1 (6.25%)
Menopausal status
Premenopausal 2 (12.5%)
Postmenopausal 14 (87.5%)
Median body mass index 27.6 kg/m2 (20.3–52.7)
Number of co-morbidities
0–1 13 (81%)
2–3 3 (19%)
4–5 0 (0%)
Stage at diagnosis
Non metastatic 11 (69%)
Locally recurrent/ metastatic 5 (31%)
Sites of metastases at time of AI initiation
Lung 12 (75%)
[Lung as only site of metastases] 10 (62.5%)
Pelvis 4 (25%)
Peritoneum 3 (19%)
Tumour volume at time of AI initiation
Low 6 (37.5%)
High 10 (62.5%)
Number of metastases
Oligometastatic 7 (44%)
Multiple 9 (56%)
AI, aromatase inhibitor.
Table 2 Tumour characteristics in the 1st line endocrine
setting (n = 16)
Variable n = 16 (%)
Histological grade (Stanford)
Low 8 (50%)
High 8 (50%)
Histological grade (FNCLCC)
Low 7 (44%)
Intermediate 3 (19%)
High 6 (37%)
Hormone receptor status
ER
Moderate to strong (grade 2–3) 13 (81%)
Weak (grade 1) 3 (19%)
PgR
Moderate to strong (grade 2–3) 10 (62.5%)
Weak (grade 1) 6 (37.5%)
ER and PgR
Moderate to strong (grade 2–3) 10 (62.5%)
Weak (grade 1) 2 (12.5%)
% ER staining
>90% 10 (62.5%)
>50% 14 (87.5%)
10-50% 1 (6.25%)
Unknown 1 (6.25%)
% PgR staining
>90% 6 (37.5%)
>50% 11 (68.75%)
10-50% 1 (6.25%)
0% 2 (12.5%)
unknown 2 (12.5%)
ER, oestrogen receptor; PgR, progesterone receptor.
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patients low-grade ULMS (50%; Table 2). Due to the
small number of our patients, we eventually analysed
them according to Stanford USMT criteria.
ER status was determined semi-quantitatively in all
(n = 16) patients, and assigned as ‘weak’, ‘moderate’ or
‘strong’ in tumour nuclei. Three of these 16 patients
(19%) had weak (1+) ER positive staining, while 13
patients (81%) had moderate to strong (2-3+) ER posi-
tive staining. With regards to PgR status: 10 (62.5%) had
a moderate to strong PgR staining, and 6 (37.5%) had a
weak PgR staining. Of the 10 patients with moderate to
strong PgR positive disease, all were also moderately to
strongly ER positive (Table 2). Moreover, in Table 2 is
depicted the classification of tumours by the extent ofER/PgR as reported by the percentage of tumour
expressing each receptor [17].
Prior surgical and systemic treatment details are pro-
vided in Table 3. All of the 16 evaluable patients had
measurable disease at time of AI treatment. Six (37.5%)
patients had low volume (defined as the absence of any
tumour deposit >2 cm in longest diameter on radio-
graphic imaging) measurable disease [16]. However, 10
(62.5%) had multiple metastases, with only one of these
having low volume disease. Sites of disease included lung
in 12 patients (75%), pelvis in 4 (25%) and peritoneum
in 3 (19%).
Four patients (25%) received hormonal replacement
therapy (HRT) with a median duration of treatment of
48 months (24–96; Table 3). Three patients progressed
Table 3 Patient treatment details (n = 16)
Variable - 1st line n (%), median (range)
Initial management at diagnosis
of ULMS
Surgical resection alone 3 (19%)
Surgical resection and BSO 13 (81%)
Number of prior chemotherapy
regimens
0 12 (75%)
1 2 (12.5%)
2 2 (12.5%)
Prior exogenous estrogens
Tamoxifen 3 (19%) , 60 months
HRT 4 (25%), 48 months (24–96)
Prior pelvic radiotherapy 1 (6%)
Median interval between diagnosis
(surgery) and letrozole initiation
37 months (2–308)
ULMS, uterine leiomyosarcoma; BSO, bilateral salpingo-oophorectomy; HRT,
hormonal replacement therapy.
Table 4 Patient and tumour characteristics in the 2nd line
endocrine setting (n = 6)
Variable -2nd line n (%), median (range)
Median age at AI initiation 56 years (40–74)
Performance status
0 2 (33%)
1 4 (67%)
Menopausal status
Premenopausal 1 (17%)
Postmenopausal 5 (83%)
Number of co-morbidities
0-1 5 (83%)
2-3 1 (17%)
Sites of metastases at time of AI initiation
Lung 4 (67%)
[Lung as only site of metastases] 4 (67%)
Peritoneum/pelvis 2 (33%)
Tumour volume at time of AI initiation
Low 2 (33%)
High 4 (67%)
Histological grade (Stanford)
Low 5 (83%)
High 1 (17%)
Hormone receptor status
ER
Moderate to strong (grade 2–3) 5 (83%)
Weak (grade 1) 1 (17%)
PgR
Moderate to strong (grade 2–3) 4 (67%)
Weak (grade 1)/ NA 2 (33%)
ER and PgR
Moderate to strong (grade 2–3) 4 (67%)
Weak (grade 1) 1 (17%)
% ER staining
>90% 5 (83%)
unknown 1 (17%)
% PgR staining
>90% 2 (33%)
>50% 3 (50%)
0% 1 (17%)
unknown 2 (33%)
AI, aromatase inhibitor; ER, oestrogen receptor; PgR, progesterone receptor.
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disease (equivalent to partial response with hormonal
manipulation) in two patients that lasted for 10 months
and 84 months respectively, while the other patient
started treatment with letrozole. Three (19%) of the 16
patients received tamoxifen (Table 3); two of them were
diagnosed with early breast cancer prior to their diagno-
sis of ULMS (and one of them also received HRT), while
the third received tamoxifen as a therapeutic manoeuvre
for ULMS and progressed one month later.
Aromatase inhibitors as 1st line endocrine therapy
Letrozole was prescribed as 1st line therapy (2.5 mg daily)
in all 16 patients (Table 1). Goserelin, a gonadotropin-
releasing hormone agonist, was administered to sup-
press ovarian function in the two premenopausal
women of our cohort, in order to permit treatment with
an AI. One patient switched from letrozole to anastro-
zole due to side effects and eventually stopped treat-
ment due to poor tolerance. Twelve (75%) patients
received AI as 1st line treatment without receiving any
anticancer agent prior to AI. Two patients had received
gemcitabine plus docetaxel prior to 1st line AI, with one
of them starting letrozole as maintenance treatment.
The other two patients received two lines of chemother-
apy prior to starting 1st line letrozole.
Aromatase inhibitors as 2nd line endocrine treatment
From these 16 patients, 6 of them received 2nd line endo-
crine treatment with exemestane (25 mg; 5 patients) or
anastrozole (1 mg; 1 patient), when their disease pro-
gressed. The demographics and tumour characteristics of
those 6 patients are listed in Table 4. The median age attime of 2nd line AI initiation was 56 years (range 40–74).
One patient was premenopausal; hence goserelin was
prescribed to suppress ovarian function. Five out of
6 tumours were classified as low-grade ULMS. With
regards to ER and PgR status, five patients had moderate
Thanopoulou et al. Clinical Sarcoma Research 2014, 4:5 Page 5 of 8
http://www.clinicalsarcomaresearch.com/content/4/1/5to strong (grade 2–3) ER with the four of them having
also grade 2–3 PgR staining. Moreover, five patients had
very high expression of ER (>90%; Table 4). All patients
had measurable disease at time of 2nd line AI treat-
ment; 4 patients had progressed in the lung and the
other 2 patients to the pelvis and peritoneum (Table 4).
Objective responses to 1st line with aromatase inhibitor
The median duration of 1st line treatment with letrozole
was 13 months (range 2–29). No patient achieved a CR,
while PR was observed in 2 (12.5%). The first patient
had low-grade ULMS strongly ER and PgR positive with
low volume peritoneal disease. The other had high
grade, moderately ER and PgR positive, oligometastatic
disease and received letrozole as maintenance treatment
after completing 6 cycles of chemotherapy, which may
make difficult to assess accurately the therapeutic impact
of letrozole alone. The duration of response in these
patients was 10 and 11 months respectively.
Ten patients (62.5%) had SD as best response, with 8
of them maintaining it for more than 6 months. The
duration of stable disease (median PFS) was 20.5 months
(95% CI: 8.7 – 32.2 months), with 8 patients stopping
letrozole because of disease progression, one because of
poor tolerance, while one is still on letrozole (27+ months).
Six of these patients had low-grade ULMS according to
both grading systems and the remaining four had high-
grade disease. ER status for all except one patient with
SD was moderate to strong, while 7 patients were strongly
PgR positive, 2 PgR negative and 1 patient had unknown
PgR status. The CBR (CR + PR + SD >6 months) was
62.5% (10/16 patients).
Best response was progression of disease (PD) in 4
patients (25%). Three patients had high-grade disease;
2 patients had weak staining for ER and PgR, while the
third strongly expressed both receptors. The fourth
patient had low grade ULMS and ER and PgR strongly
positive and she received letrozole after progressing on
two previous lines of chemotherapy with symptomatic
high volume disease.
Objective responses to 2nd line with aromatase inhibitor
The median duration of 2nd line AI therapy was
3 months (range 3–22 months). One patient achieved
PR (after progression of peritoneal disease) but stopped
treatment after 3 months due to toxicity. She had low
grade, strongly ER and PgR positive disease.
Three patients had SD as best response and are
continuing to date (duration of treatment 2, 6 and
22 months respectively). All of them had high volume
disease with multiple lung metastases. Moreover all had
low grade ULMS, with two of them expressing strongly
both receptors and the third being weakly ER positive
with unknown PgR status.Two patients (on anastrozole and exemestane re-
spectively) had PD as best response (duration of treat-
ment 3 months); one of them with low-grade, strongly
ER and PgR positive disease was switched to 3rd line
treatment with exemestane, while the other patient
had high grade, strongly ER/PgR positive disease and
was eventually treated with 1st line chemotherapy.
Progression-free survival of 1st line with aromatase
inhibitor
At last follow-up, 4 (25%) of the 16 patients had died
with disease progression, 5 (31%) were alive with
disease progression, 2 (12.5%) were alive on 1st line
letrozole without progression, 2 (12.5%) patients had
stopped letrozole and exemestane respectively due to
toxicity and were alive without progression and 3
(19%) patients were alive on 2nd line exemestane with-
out progression (Figure 1). Median PFS for 1st line
letrozole was 14 months (95% CI: 0–30 months). The
1-year progression-free rate was 63% (95% CI: 39%-87%).
Figure 2 illustrates the difference in PFS in 1st line
treatment with letrozole between patients with moder-
ate and strong ER and/or PgR status and those with
tumours with weak ER and PgR status. Patients with
both hormone receptors moderately to strongly positive
had superior median PFS [20 months (95% CI: 7– 34)]
compared to those with weak ER and PgR expression
[median PFS 12 months (95% CI: 0 – 29)]. However,
due to the small number of patients it is not possible to
drive safe conclusions due to lack of statistical signifi-
cance in the overall cohort analysis.
Moreover, patients with low-grade ULMS (n = 8) had
superior median PFS [20 months (95% CI: 7 – 34)],
compared to those with high-grade ULMS [n = 8;
median PFS 11 months (95% CI: 0 – 30)], as demonstrated
in Figure 2b. Accordingly, the 1-year progression-free rate
for the low-grade ULMS was 75% (95% CI: 45% - 100%)
compared to 50% (15% - 87%) in the high grade ULMS.
Progression-free survival of 2nd line with aromatase
inhibitor
Median PFS for the 2nd line AI has not been reached
after a median follow-up of 6 months. The 1-year
progression-free rate for the 2nd line AI was 80% (95% CI:
21% - 97%).
Toxicities during aromatase inhibitor treatment - any
dose reduction/ discontinuation
Toxicities during the 1st line treatment with letrozole
were noted among 31% of patients and all were mild
(grade 1–2); specifically, hot flushes were recorded in 5
patients (31%), lethargy in 4 (25%), arthralgias/myalgias
in 4 (25%), and weight gain in 1 patient (6%). One
patient developed osteoporosis and started supplementation
Progression free survival
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Figure 1 Progression free survival defined as date of start of first line treatment to date of progression or death.
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sea and chest tightness and eventually discontinued
anastrozole.
During the 2nd line treatment only one patient devel-
oped grade 1 arthralgias and another (premenopausal)
developed grade 2 hot flushes, headaches and rashes
and discontinued treatment. The rate of discontinuation
of AIs secondary to toxicity among all patients was low
(2/16 patients).
Discussion
Progestins were among the first hormonal modulators to
be explored in the management of metastatic ULMS [1].
However, AIs are currently the preferred hormonal
agents for 1st line treatment, because of their higha Progression free survival
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hormone receptor status. b. Progression free survival stratified by tumour gtherapeutic index. Moreover, AIs have shown activity as
2nd line treatment in progestin-resistant ULMS [1].
This case series adds the data regarding the role of AIs
in the management of patients with hormone positive
ULMS [15-17], though the results should be interpreted
cautiously, as our study is retrospective and the number
of patients is small. In our cohort of 16 patients, with
measurable advanced hormone positive ULMS, objective
response was observed in 12.5%, and clinical benefit rate
in 62.5%; median PFS was 14 months (95% CI: 0 – 30).
Moreover, prolonged PFS was more likely to be ob-
served in patients with low grade compared to high
grade ULMS [20 months (95% CI: 7 – 34) vs. 11 months
(95% CI: 0 – 30)]. Similarly, prolonged PFS was more
likely to be observed in patients with moderately tob Progression free survival
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weakly hormone receptors’ expression [20 months (95% CI:
7– 34) vs. 12 months (95% CI: 0 – 29)].
To our knowledge, this is the first case series of
advanced hormone positive ULMS reporting outcomes
of 2nd line endocrine treatment. In our cohort of 6
patients, objective response was observed in 1 patient
(PR), who had low grade strongly ER/PgR positive
disease (>90% ER expression). Three patients had SD
and are continuing to date, the two of them for more
than 6 months (CBR = 50%; 3/6 patients). All of them
had high volume disease, low grade ULMS, and two
of them were strongly ER ER/PgR positive (>90% ER
expression). Two patients progressed (strongly ER/PgR
positive, high-grade ULMS).
In terms of side effects, a constellation of oestrogen
deprivation symptoms were the reason for discontinu-
ation of AIs in 2 out of the 16 patients (12%). Moreover,
the detrimental effect of HRT and tamoxifen has also
been shown in our study, with withdrawal of HRT lead-
ing to disease regression in three patients [1].
In both our and O’Cearbhaill et al. [16] retrospecitve
studies, patients with low grade ULMS had superior PFS
compared to patients with high grade ULMS; both stud-
ies used the Stanford USMT criteria for grade [19],
though grade has not been found to be of prognostic
significance in ULMS [22]. In the only prospective
phase II trial of letrozole as 1st line in patients with
advanced ULMS [17] they used mitotic index, which
has been shown to have prognostic significance [22,23].
There was no significant association found between
mitotic index and PFS [17]. Of note, currently there is no
formally validated grading system for ULMS [16,18,19].
In the only prospective trial of George et al. [17], the
best response was stable disease in (14/26) of patients.
The median PFS was 12 weeks for the whole cohort,
but 3 patients with high expression of both ER and
PgR (>90%) were free of disease progression after
6 months on study [17]. Moreover, there was a signifi-
cant association between ER status (>90%) and pro-
longed PFS, while such association was not confirmed
with mitotic index [17]. In the largest retrospective
study in 34 patients with advanced ULMS, the best
objective response of AIs was partial response in 9% of
patients, all of whom were ER positive; the CBR was
41% [16]. The median PFS was 2.9 months, although
both objective responses and prolonged PFS were more
likely to be observed in patients with ER and/or PgR
expression [16].
By adding our findings to the above studies, it can be
deducted that there is a correlation between high (>90%)
ER and PgR expression and prolonged PFS in 1st line
treatment with AIs. The slight differences between the
published ORR and PFS of the phase II trial and ourdata may merely reflect the difference in the percentage
of patients that were strongly ER/PgR positive. In the
phase II trial, only 11% (3/26) of patients’ tumours
expressed ER in >90% of tumour cells [17], while in our
cohort, 62.5% (10/16) of patients had tumours that
expressed ER in >90% of cells. Such detailed description
on the intensity of ER expression of the ULMS tumours
was not presented in other retrospective study [16].
The above data may also suggest that the ER and PgR
expression may not be only a prognostic factor [10,13],
but also a predictive marker in ULMS, although the pre-
cise role of hormone receptors in the molecular biology
of ULMS remains unclear [17]. The significant prolonga-
tion of PFS in patients with very strong expression of
ER/PgR, in both our study and the recently published
trial [17], suggest that AIs may play an active therapeutic
role in this hormone-drive subtype of ULMS, whose ER
cut-off status is set to 90%.
Conclusions
There is clearly a subset of ULMS with a more indolent
clinical behaviour, which is clinically characterised by
disease-free interval greater than 6 months [24]. This
ULMS subset seems to be mostly ER/PgR [13,16] and
includes patients that often present with low-volume
disease [16]. In line with the published studies [16,17],
AIs could be considered active agents for 1st line treat-
ment in hormone positive advanced ULMS, preferably
for these highly selected ULMS patients with strongly
ER and/or PgR positive status (>90%) and/or low grade
and/or low volume disease, as it appears to be more
limited in unselected cohorts [16,17]. Moreover, in such
highly selected patients with advanced ULMS, it could also
be considered 2nd line treatment with exemestane (ster-
oidal AI), in view of the positive outcomes in our small
cohort (CBR: 50%). As expected, AIs were well tolerated.
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